Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
Background: The surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal squamous cell carcinoma (ESCC) remains unelucidated. This study aimed to determine the validity of PFS as a surrogate endpoint for OS in ESCC patients treated with definitive radiotherapy or definiti...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-10-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359221131526 |
| _version_ | 1811335046297026560 |
|---|---|
| author | Weiming Han Lan Wang Chen Li Junqiang Chen Wencheng Zhang Xin Wang Qingsong Pang Yidian Zhao Xinchen Sun Kaixian Zhang Gaofeng Li Ling Li Xueying Qiao Miaoling Liu Yadi Wang Lei Deng Wenqing Wang Nan Bi Tao Zhang Wei Deng Wenjie Ni Xiao Chang Zongmei Zhou Jun Liang Qinfu Feng Lvhua Wang Dongfu Chen Jima Lv Shuchai Zhu Chun Han Zefen Xiao |
| author_facet | Weiming Han Lan Wang Chen Li Junqiang Chen Wencheng Zhang Xin Wang Qingsong Pang Yidian Zhao Xinchen Sun Kaixian Zhang Gaofeng Li Ling Li Xueying Qiao Miaoling Liu Yadi Wang Lei Deng Wenqing Wang Nan Bi Tao Zhang Wei Deng Wenjie Ni Xiao Chang Zongmei Zhou Jun Liang Qinfu Feng Lvhua Wang Dongfu Chen Jima Lv Shuchai Zhu Chun Han Zefen Xiao |
| author_sort | Weiming Han |
| collection | DOAJ |
| description | Background: The surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal squamous cell carcinoma (ESCC) remains unelucidated. This study aimed to determine the validity of PFS as a surrogate endpoint for OS in ESCC patients treated with definitive radiotherapy or definitive chemoradiotherapy (dRT/dCRT), as well as characterize the prognostic factors and survival of such patients. Methods: A total of 3662 patients from 10 cancer centers were enrolled. One-, 2-, and 3-year PFS (PFS12, PFS24, and PSF36, respectively) were used as time points for analysis. At each time point, ESCC-specific mortality and OS were characterized using competing risk and conditional survival models, while correlation between PFS and OS was evaluated by linear regression. Results: At PFS12, PFS24, and PFS36, a progressive decrease in 5-year ESCC-specific mortality (35.2%–13.4%) and increase in 5-year OS (46.6%–62.9%) were observed. Regardless, the OS of patients remained markedly lower than those of the age- and sex-matched Chinese general population. TNM stage remained a significant prognostic factor at PFS36. Strong correlation was found between 3-year PFS and 5-year OS, which was further externally validated. Conclusions: Three-year PFS may act as a potential surrogate endpoint for 5-year OS. TNM stage was considered a significant prognostic factor for OS, and may represent the optimal prognostic tool to guide clinical decision-making and post-treatment follow-up. |
| first_indexed | 2024-04-13T17:18:11Z |
| format | Article |
| id | doaj.art-1e122a2995cf43e3b80ec255001bd211 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-13T17:18:11Z |
| publishDate | 2022-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-1e122a2995cf43e3b80ec255001bd2112022-12-22T02:38:03ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592022-10-011410.1177/17588359221131526Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysisWeiming HanLan WangChen LiJunqiang ChenWencheng ZhangXin WangQingsong PangYidian ZhaoXinchen SunKaixian ZhangGaofeng LiLing LiXueying QiaoMiaoling LiuYadi WangLei DengWenqing WangNan BiTao ZhangWei DengWenjie NiXiao ChangZongmei ZhouJun LiangQinfu FengLvhua WangDongfu ChenJima LvShuchai ZhuChun HanZefen XiaoBackground: The surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal squamous cell carcinoma (ESCC) remains unelucidated. This study aimed to determine the validity of PFS as a surrogate endpoint for OS in ESCC patients treated with definitive radiotherapy or definitive chemoradiotherapy (dRT/dCRT), as well as characterize the prognostic factors and survival of such patients. Methods: A total of 3662 patients from 10 cancer centers were enrolled. One-, 2-, and 3-year PFS (PFS12, PFS24, and PSF36, respectively) were used as time points for analysis. At each time point, ESCC-specific mortality and OS were characterized using competing risk and conditional survival models, while correlation between PFS and OS was evaluated by linear regression. Results: At PFS12, PFS24, and PFS36, a progressive decrease in 5-year ESCC-specific mortality (35.2%–13.4%) and increase in 5-year OS (46.6%–62.9%) were observed. Regardless, the OS of patients remained markedly lower than those of the age- and sex-matched Chinese general population. TNM stage remained a significant prognostic factor at PFS36. Strong correlation was found between 3-year PFS and 5-year OS, which was further externally validated. Conclusions: Three-year PFS may act as a potential surrogate endpoint for 5-year OS. TNM stage was considered a significant prognostic factor for OS, and may represent the optimal prognostic tool to guide clinical decision-making and post-treatment follow-up.https://doi.org/10.1177/17588359221131526 |
| spellingShingle | Weiming Han Lan Wang Chen Li Junqiang Chen Wencheng Zhang Xin Wang Qingsong Pang Yidian Zhao Xinchen Sun Kaixian Zhang Gaofeng Li Ling Li Xueying Qiao Miaoling Liu Yadi Wang Lei Deng Wenqing Wang Nan Bi Tao Zhang Wei Deng Wenjie Ni Xiao Chang Zongmei Zhou Jun Liang Qinfu Feng Lvhua Wang Dongfu Chen Jima Lv Shuchai Zhu Chun Han Zefen Xiao Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis Therapeutic Advances in Medical Oncology |
| title | Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis |
| title_full | Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis |
| title_fullStr | Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis |
| title_full_unstemmed | Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis |
| title_short | Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis |
| title_sort | progression free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma a real world data and literature based analysis |
| url | https://doi.org/10.1177/17588359221131526 |
| work_keys_str_mv | AT weiminghan progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT lanwang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT chenli progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT junqiangchen progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT wenchengzhang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT xinwang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT qingsongpang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT yidianzhao progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT xinchensun progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT kaixianzhang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT gaofengli progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT lingli progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT xueyingqiao progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT miaolingliu progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT yadiwang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT leideng progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT wenqingwang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT nanbi progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT taozhang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT weideng progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT wenjieni progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT xiaochang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT zongmeizhou progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT junliang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT qinfufeng progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT lvhuawang progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT dongfuchen progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT jimalv progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT shuchaizhu progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT chunhan progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis AT zefenxiao progressionfreesurvivalassurrogateendpointofoverallsurvivalinesophagealsquamouscellcarcinomaarealworlddataandliteraturebasedanalysis |